ES2926480T3 - Dispositivos y sistemas retentivos para la liberación in situ de principios activos farmacéuticos - Google Patents

Dispositivos y sistemas retentivos para la liberación in situ de principios activos farmacéuticos Download PDF

Info

Publication number: ES2926480T3
Authority: ES; Spain
Prior art keywords: film; compartment; stomach; gastric retention; active ingredient
Prior art date: 2013-12-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES14824124T

Other languages

English (en)

Spanish (es)

Inventor

Nir Betser

Valery Artmanov

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Epitomee Medical Ltd

Original Assignee

Epitomee Medical Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-05

Filing date

2014-12-04

Publication date

2022-10-26

2014-12-04 Application filed by Epitomee Medical Ltd filed Critical Epitomee Medical Ltd

2022-10-26 Application granted granted Critical

2022-10-26 Publication of ES2926480T3 publication Critical patent/ES2926480T3/es

Status Active legal-status Critical Current

2034-12-04 Anticipated expiration legal-status Critical

Links

238000011065 in-situ storage Methods 0.000 title abstract description 4
239000008186 active pharmaceutical agent Substances 0.000 title description 2
230000002496 gastric effect Effects 0.000 claims abstract description 112
230000014759 maintenance of location Effects 0.000 claims abstract description 92
239000002552 dosage form Substances 0.000 claims abstract description 60
150000001875 compounds Chemical class 0.000 claims description 95
210000002784 stomach Anatomy 0.000 claims description 78
239000004480 active ingredient Substances 0.000 claims description 56
239000007788 liquid Substances 0.000 claims description 22
239000004615 ingredient Substances 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 16
238000009472 formulation Methods 0.000 claims description 11
238000013270 controlled release Methods 0.000 claims description 9
238000011068 loading method Methods 0.000 claims description 8
230000015556 catabolic process Effects 0.000 claims description 7
238000006731 degradation reaction Methods 0.000 claims description 7
238000000034 method Methods 0.000 abstract description 10
239000013543 active substance Substances 0.000 abstract 2
239000010410 layer Substances 0.000 description 63
229940079593 drug Drugs 0.000 description 38
239000003814 drug Substances 0.000 description 38
239000012530 fluid Substances 0.000 description 32
239000002775 capsule Substances 0.000 description 27
-1 for example Substances 0.000 description 22
239000000499 gel Substances 0.000 description 16
108010025899 gelatin film Proteins 0.000 description 13
210000001187 pylorus Anatomy 0.000 description 9
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
230000005484 gravity Effects 0.000 description 8
239000000463 material Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
230000008961 swelling Effects 0.000 description 8
239000002202 Polyethylene glycol Substances 0.000 description 7
229920002125 Sokalan® Polymers 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 6
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000012729 immediate-release (IR) formulation Substances 0.000 description 6
229960004502 levodopa Drugs 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229920001661 Chitosan Polymers 0.000 description 5
229960004150 aciclovir Drugs 0.000 description 5
230000036760 body temperature Effects 0.000 description 5
AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 5
229960002626 clarithromycin Drugs 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 5
239000004014 plasticizer Substances 0.000 description 5
230000002035 prolonged effect Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
229920000247 superabsorbent polymer Polymers 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
239000011668 ascorbic acid Substances 0.000 description 4
229960005070 ascorbic acid Drugs 0.000 description 4
235000010323 ascorbic acid Nutrition 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
229960001380 cimetidine Drugs 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 4
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
238000013265 extended release Methods 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
229960003105 metformin Drugs 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
239000004584 polyacrylic acid Substances 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
239000002356 single layer Substances 0.000 description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010020346 Polyglutamic Acid Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
229960003459 allopurinol Drugs 0.000 description 3
229940069428 antacid Drugs 0.000 description 3
239000003159 antacid agent Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000010216 calcium carbonate Nutrition 0.000 description 3
238000005266 casting Methods 0.000 description 3
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 3
229960003405 ciprofloxacin Drugs 0.000 description 3
229960002656 didanosine Drugs 0.000 description 3
210000001198 duodenum Anatomy 0.000 description 3
235000020774 essential nutrients Nutrition 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
229920002674 hyaluronan Polymers 0.000 description 3
229960003160 hyaluronic acid Drugs 0.000 description 3
239000000017 hydrogel Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 3
229920002643 polyglutamic acid Polymers 0.000 description 3
235000015497 potassium bicarbonate Nutrition 0.000 description 3
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
210000005070 sphincter Anatomy 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000001069 triethyl citrate Substances 0.000 description 3
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
235000013769 triethyl citrate Nutrition 0.000 description 3
229940093257 valacyclovir Drugs 0.000 description 3
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 2
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000016942 Elastin Human genes 0.000 description 2
108010014258 Elastin Proteins 0.000 description 2
108010061435 Enalapril Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 2
229930010555 Inosine Natural products 0.000 description 2
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
108010007859 Lisinopril Proteins 0.000 description 2
229920003091 Methocel™ Polymers 0.000 description 2
RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
239000003513 alkali Substances 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229940118662 aluminum carbonate Drugs 0.000 description 2
229940024545 aluminum hydroxide Drugs 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
229960002274 atenolol Drugs 0.000 description 2
229960005370 atorvastatin Drugs 0.000 description 2
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
229960004099 azithromycin Drugs 0.000 description 2
229960000794 baclofen Drugs 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
229960004530 benazepril Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
150000001621 bismuth Chemical class 0.000 description 2
238000007664 blowing Methods 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
229960004205 carbidopa Drugs 0.000 description 2
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229960004195 carvedilol Drugs 0.000 description 2
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
229940106164 cephalexin Drugs 0.000 description 2
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
229960005025 cilazapril Drugs 0.000 description 2
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000010276 construction Methods 0.000 description 2
235000019820 disodium diphosphate Nutrition 0.000 description 2
GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
229920002549 elastin Polymers 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
229960000873 enalapril Drugs 0.000 description 2
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 2
229960003337 entacapone Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
229960001596 famotidine Drugs 0.000 description 2
229960000304 folic acid Drugs 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
229960002490 fosinopril Drugs 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
235000011087 fumaric acid Nutrition 0.000 description 2
229960003883 furosemide Drugs 0.000 description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
229960002870 gabapentin Drugs 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
230000030136 gastric emptying Effects 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
235000013773 glyceryl triacetate Nutrition 0.000 description 2
229960004553 guanabenz Drugs 0.000 description 2
229960002003 hydrochlorothiazide Drugs 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
229950009810 indolapril Drugs 0.000 description 2
229960003786 inosine Drugs 0.000 description 2
238000003475 lamination Methods 0.000 description 2
229960003174 lansoprazole Drugs 0.000 description 2
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 2
229960002394 lisinopril Drugs 0.000 description 2
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
229910052808 lithium carbonate Inorganic materials 0.000 description 2
229940008015 lithium carbonate Drugs 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
229960004844 lovastatin Drugs 0.000 description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
229960000869 magnesium oxide Drugs 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
239000001630 malic acid Substances 0.000 description 2
235000011090 malic acid Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
229960002237 metoprolol Drugs 0.000 description 2
229960000282 metronidazole Drugs 0.000 description 2
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
229960003793 midazolam Drugs 0.000 description 2
229960005249 misoprostol Drugs 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229960001783 nicardipine Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
229960000715 nimodipine Drugs 0.000 description 2
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 2
229960000564 nitrofurantoin Drugs 0.000 description 2
229960004872 nizatidine Drugs 0.000 description 2
SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
229960000381 omeprazole Drugs 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
229960001243 orlistat Drugs 0.000 description 2
229960004570 oxprenolol Drugs 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
229960005019 pantoprazole Drugs 0.000 description 2
239000002245 particle Substances 0.000 description 2
229960002582 perindopril Drugs 0.000 description 2
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
230000002572 peristaltic effect Effects 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
229960005414 pirbuterol Drugs 0.000 description 2
229960004633 pirenzepine Drugs 0.000 description 2
RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
229920000193 polymethacrylate Polymers 0.000 description 2
229920002689 polyvinyl acetate Polymers 0.000 description 2
239000011118 polyvinyl acetate Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000011736 potassium bicarbonate Substances 0.000 description 2
229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
229960002965 pravastatin Drugs 0.000 description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
229960001289 prazosin Drugs 0.000 description 2
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
229960001233 pregabalin Drugs 0.000 description 2
238000003825 pressing Methods 0.000 description 2
239000006041 probiotic Substances 0.000 description 2
230000000529 probiotic effect Effects 0.000 description 2
235000018291 probiotics Nutrition 0.000 description 2
230000008569 process Effects 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229960003712 propranolol Drugs 0.000 description 2
229960001455 quinapril Drugs 0.000 description 2
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
229960003401 ramipril Drugs 0.000 description 2
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
229960000620 ranitidine Drugs 0.000 description 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
229960000329 ribavirin Drugs 0.000 description 2
229960003320 roxatidine Drugs 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
229960003946 selegiline Drugs 0.000 description 2
229960002855 simvastatin Drugs 0.000 description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
229940001089 sinemet Drugs 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
229940103422 stalevo Drugs 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960004291 sucralfate Drugs 0.000 description 2
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
229960003708 sumatriptan Drugs 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
229950004351 telenzepine Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
229960001177 trimetazidine Drugs 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
229960003636 vidarabine Drugs 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
238000009736 wetting Methods 0.000 description 2
229960002769 zofenopril Drugs 0.000 description 2
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 2
JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
229920003148 Eudragit® E polymer Polymers 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
229920003072 Plasdone™ povidone Polymers 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920000147 Styrene maleic anhydride Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
150000003926 acrylamides Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
238000004026 adhesive bonding Methods 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229940008474 alka-seltzer Drugs 0.000 description 1
CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229940087430 biaxin Drugs 0.000 description 1
229960004645 bismuth subcitrate Drugs 0.000 description 1
ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
229960000782 bismuth subsalicylate Drugs 0.000 description 1
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 1
230000009172 bursting Effects 0.000 description 1
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
229940095498 calcium polycarbophil Drugs 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
239000002131 composite material Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
BLCTWBJQROOONQ-UHFFFAOYSA-N ethenyl prop-2-enoate Chemical compound C=COC(=O)C=C BLCTWBJQROOONQ-UHFFFAOYSA-N 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000007667 floating Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
229940095884 glucophage Drugs 0.000 description 1
229940093617 glumetza Drugs 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
239000012633 leachable Substances 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229960001708 magnesium carbonate Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002921 methylnaltrexone Drugs 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
229960000939 metoprolol succinate Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000005192 partition Methods 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001141 propulsive effect Effects 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
229960004034 sitagliptin Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
PERKCQYZRBLRLO-UHFFFAOYSA-M sodium;2-acetyloxybenzoic acid;hydrogen carbonate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC([O-])=O.CC(=O)OC1=CC=CC=C1C(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O PERKCQYZRBLRLO-UHFFFAOYSA-M 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004583 superabsorbent polymers (SAPs) Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229940090016 tegretol Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
229960003107 tramadol hydrochloride Drugs 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
229960004688 venlafaxine Drugs 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000003466 welding Methods 0.000 description 1
HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
229960004010 zaleplon Drugs 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1
229940107931 zovirax Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
- A61M2210/1053—Stomach

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)

ES14824124T 2013-12-05 2014-12-04 Dispositivos y sistemas retentivos para la liberación in situ de principios activos farmacéuticos Active ES2926480T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361912204P	2013-12-05	2013-12-05
PCT/IL2014/051063 WO2015083171A1 (fr)	2013-12-05	2014-12-04	Dispositifs et systèmes de rétention pour la libération in-situ d'agents pharmaceutiques actifs

Publications (1)

Publication Number	Publication Date
ES2926480T3 true ES2926480T3 (es)	2022-10-26

Family

ID=52282802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES14824124T Active ES2926480T3 (es)	2013-12-05	2014-12-04	Dispositivos y sistemas retentivos para la liberación in situ de principios activos farmacéuticos

Country Status (10)

Country	Link
US (1)	US11129793B2 (fr)
EP (1)	EP3091962B1 (fr)
JP (3)	JP2017502935A (fr)
CN (2)	CN105899198A (fr)
AU (1)	AU2014358675B2 (fr)
BR (1)	BR112016012615B1 (fr)
CA (1)	CA2932574C (fr)
ES (1)	ES2926480T3 (fr)
IL (1)	IL245987B (fr)
WO (1)	WO2015083171A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013183058A2 (fr)	2012-06-07	2013-12-12	Tulip Medical Ltd.	Dispositif étendu
EP3091962B1 (fr) *	2013-12-05	2022-06-08	Epitomee Medical Ltd.	Dispositifs et systèmes de rétention pour la libération in-situ d'agents pharmaceutiques actifs
US20170266112A1 (en)	2014-06-11	2017-09-21	Massachusetts Institute Of Technology	Residence structures and related methods
NZ727659A (en)	2014-06-11	2021-12-24	Massachusetts Inst Technology	Residence structures and related methods
US11576859B2 (en)	2015-10-23	2023-02-14	Lyndra Therapeutics, Inc.	Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (fr)	2015-12-08	2017-06-15	Lyndra, Inc.	Configurations géométriques de systèmes à résidence gastrique
CN109310639A (zh)	2016-05-27	2019-02-05	林德拉有限公司	用于胃驻留系统的材料结构
JP2019532947A (ja)	2016-09-30	2019-11-14	リンドラ，インコーポレイティド	アダマンタン系薬物の持続的送達のための胃内滞留システム
CN110035718B (zh)	2016-12-02	2021-04-06	克雷西奥生物科技有限公司	胃内滞留系统
CA3066658A1 (fr)	2017-06-09	2018-12-13	Lyndra, Inc.	Systemes gastriques a demeure avec films modulant le taux de liberation
US11793751B2 (en) *	2017-09-20	2023-10-24	Lyndra Therapeutics, Inc.	Encapsulation of gastric residence systems
WO2019111132A1 (fr)	2017-12-04	2019-06-13	Clexio Biosciences Ltd.	Système de résidence gastrique à action prolongée
CN108721246B (zh) *	2018-05-29	2021-06-25	王喆明	高分子材料构建的多单元超长效口服制剂及其制备方法
WO2020102629A1 (fr) *	2018-11-15	2020-05-22	Massachusetts Institute Of Technology	Dispositifs à demeure à commande thermique
US11389398B2 (en)	2019-05-14	2022-07-19	Clexio Biosciences Ltd.	Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US12544310B2 (en)	2020-03-02	2026-02-10	Craft Health Pte Ltd.	Method of manufacturing oral dosage forms for extended drug release
CA3200821A1 (fr)	2020-12-07	2022-06-16	Gil Cohen	Dispositifs expansibles intragastriques
KR20230170674A (ko) *	2021-03-15	2023-12-19	이피토미 메디칼 엘티디	활성제를 조직으로 전달하기 위한 확장가능한 디바이스
WO2022195476A1 (fr)	2021-03-15	2022-09-22	Clexio Biosciences Ltd.	Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques
JP2024531127A (ja) *	2021-08-09	2024-08-29	マサチューセッツインスティテュートオブテクノロジー	摂取可能デバイス
AU2023346631A1 (en) *	2022-09-21	2025-05-01	Epitomee Medical Ltd.	Controllably disintegrable self-expandable ingestible devices
EP4604932A1 (fr) *	2022-10-18	2025-08-27	Triastek, Inc.	Formes galéniques orales de medicaments pour rétention dans l'estomac
CN116077417B (zh) *	2022-12-29	2024-03-22	汤臣倍健股份有限公司	一种胃滞留片剂及制备方法
CN117800668A (zh) *	2023-11-14	2024-04-02	苏州上建杭鑫混凝土有限公司	一种地下高抗渗耐久性混凝土

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2464693A (en)	1945-04-03	1949-03-15	Du Pont	Synthetic linear polycarbonamides
US2470665A (en)	1947-07-08	1949-05-17	Stiehl Charles William	Suction apparatus
US3584631A (en)	1969-08-25	1971-06-15	Amf Inc	Reconstituted tobacco composition
SE336642B (fr)	1969-10-28	1971-07-12	Astra Meditec Ab
US3630114A (en)	1970-04-15	1971-12-28	Du Pont	Polymeric filament sheet slitting
US3774596A (en)	1971-06-29	1973-11-27	G Cook	Compliable cavity speculum
US3840009A (en)	1971-12-27	1974-10-08	Alza Corp	Self-powered vapor pressure delivery device
US3786813A (en)	1972-12-27	1974-01-22	Alza Corp	Drug delivery device with self actuated mechanism for retaining device in selected area
US3901232A (en)	1973-10-26	1975-08-26	Alza Corp	Integrated device for administering beneficial drug at programmed rate
US3911098A (en)	1974-02-11	1975-10-07	American Cyanamid Co	Medicament carrier
US4135514A (en)	1974-12-23	1979-01-23	Alza Corporation	Osmotic releasing system for administering ophthalmic drug to eye of animal
US4027676A (en)	1975-01-07	1977-06-07	Ethicon, Inc.	Coated sutures
US4167558A (en)	1976-02-13	1979-09-11	Hoffmann-La Roche Inc.	Novel sustained release tablet formulations
US4140755A (en)	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
US4055178A (en)	1976-03-10	1977-10-25	Harrigan Roy Major	Drug delivery device for preventing contact of undissolved drug with the stomach lining
US4203439A (en)	1976-11-22	1980-05-20	Alza Corporation	Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4133315A (en)	1976-12-27	1979-01-09	Berman Edward J	Method and apparatus for reducing obesity
US4207890A (en)	1977-01-04	1980-06-17	Mcneilab, Inc.	Drug-dispensing device and method
DE2721548C2 (de)	1977-05-13	1982-11-04	Friedrich Gerd 5000 Köln Lauterjung	Sonde
WO1980000007A1 (fr)	1978-06-02	1980-01-10	A Rockey	Manchon a usage medical
US4246893A (en)	1978-07-05	1981-01-27	Daniel Berson	Inflatable gastric device for treating obesity
EP0010987B1 (fr)	1978-11-07	1983-10-05	Beecham Group Plc	Dispositif pour administrer un produit par voie buccale à un ruminant
US4311146A (en)	1980-05-08	1982-01-19	Sorenson Research Co., Inc.	Detachable balloon catheter apparatus and method
US4899747A (en)	1981-12-10	1990-02-13	Garren Lloyd R	Method and appartus for treating obesity
US4416267A (en)	1981-12-10	1983-11-22	Garren Lloyd R	Method and apparatus for treating obesity
DE3211917A1 (de)	1982-03-31	1983-10-13	Hoechst Ag, 6230 Frankfurt	Kautschukvulkanisate mit relativ niedriger haerte und verfahren zur verminderung des bei dynamischer verformung in waerme umgewandelten energieanteils der vulkanisate
US4447227A (en)	1982-06-09	1984-05-08	Endoscopy Surgical Systems, Inc.	Multi-purpose medical devices
US4485805A (en)	1982-08-24	1984-12-04	Gunther Pacific Limited Of Hong Kong	Weight loss device and method
EP0103481A1 (fr)	1982-09-14	1984-03-21	Ainsworth Nominees Proprietary Limited	Traitement et réduction de l'obésité humaine
US4607618A (en)	1983-02-23	1986-08-26	Angelchik Jean P	Method for treatment of morbid obesity
DE3409663C2 (de)	1984-03-16	1987-02-19	Fresenius AG, 6380 Bad Homburg	Medizinische Sonde
US4723547A (en)	1985-05-07	1988-02-09	C. R. Bard, Inc.	Anti-obesity balloon placement system
US4767627A (en)	1985-05-29	1988-08-30	Merck & Co., Inc.	Drug delivery device which can be retained in the stomach for a controlled period of time
JPS6248743A (ja)	1985-08-28	1987-03-03	Shin Etsu Chem Co Ltd	ゴム組成物
US4694827A (en)	1986-01-14	1987-09-22	Weiner Brian C	Inflatable gastric device for treating obesity and method of using the same
GB8603099D0 (en)	1986-02-07	1986-03-12	Blass K G	Gastrointestinal module
US4739758A (en)	1986-05-19	1988-04-26	Criticare Systems, Inc.	Apparatus for stomach cavity reduction
JPH031419Y2 (fr)	1987-01-08	1991-01-17
US4812315A (en)	1987-05-14	1989-03-14	Tarabishi M Hisham	Diet pills
US5084061A (en)	1987-09-25	1992-01-28	Gau Fred C	Intragastric balloon with improved valve locating means
WO1990000376A1 (fr)	1988-07-05	1990-01-25	Cantenys Jose	Ballon intragastrique
US4925446A (en)	1988-07-06	1990-05-15	Transpharm Group Inc.	Removable inflatable intragastrointestinal device for delivering beneficial agents
US4968294A (en)	1989-02-09	1990-11-06	Salama Fouad A	Urinary control valve and method of using same
US4984564A (en)	1989-09-27	1991-01-15	Frank Yuen	Surgical retractor device
US5206030A (en)	1990-02-26	1993-04-27	Fmc Corporation	Film-forming composition and use for coating pharmaceuticals, foods and the like
US5041364A (en)	1990-10-01	1991-08-20	Eastman Kodak Company	Diagnostic photographic elements exhibiting reduced glare following rapid access processing
US5167626A (en)	1990-10-02	1992-12-01	Glaxo Inc.	Medical capsule device actuated by radio-frequency (RF) signal
US5496535A (en)	1991-04-12	1996-03-05	Alliance Pharmaceutical Corp.	Fluorocarbon contrast media for use with MRI and radiographic imaging
US5865728A (en)	1991-05-29	1999-02-02	Origin Medsystems, Inc.	Method of using an endoscopic inflatable lifting apparatus to create an anatomic working space
US5836871A (en)	1991-05-29	1998-11-17	Origin Medsystems, Inc.	Method for lifting a body wall using an inflatable lifting apparatus
US5370134A (en)	1991-05-29	1994-12-06	Orgin Medsystems, Inc.	Method and apparatus for body structure manipulation and dissection
CA2074304C (fr)	1991-08-02	1996-11-26	Cyril J. Schweich, Jr.	Catheter pour l'administration de medicaments
US5234454A (en)	1991-08-05	1993-08-10	Akron City Hospital	Percutaneous intragastric balloon catheter and method for controlling body weight therewith
JPH0624959A (ja)	1991-10-04	1994-02-01	Bayer Yakuhin Kk	胃内浮遊型薬物徐放性固形製剤
US5259399A (en)	1992-03-02	1993-11-09	Alan Brown	Device and method of causing weight loss using removable variable volume intragastric bladder
JPH07505560A (ja)	1993-05-11	1995-06-22	ターゲット　セラピューティクス，インコーポレイテッド	一時的に膨張可能な血管内人工装具
US5443505A (en)	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
DE4412261C2 (de)	1994-04-09	1996-10-17	Jonas Konrad H	Vorrichtung zum Zusammenführen wenigstens zweier Fließmedien
US5750585A (en)	1995-04-04	1998-05-12	Purdue Research Foundation	Super absorbent hydrogel foams
US5780058A (en)	1995-07-21	1998-07-14	Alza Corporation	Oral delivery of discrete units
US5783212A (en)	1996-02-02	1998-07-21	Temple University--of the Commonwealth System of Higher Education	Controlled release drug delivery system
WO1998043611A1 (fr)	1997-03-31	1998-10-08	Alza Corporation	Systeme d'administration par diffusion, implantable
US6271278B1 (en)	1997-05-13	2001-08-07	Purdue Research Foundation	Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
JP2001527023A (ja)	1997-08-11	2001-12-25	アルザ・コーポレーション	胃で保持するのに適合した長期放出性活性剤剤形
US5893826A (en)	1997-08-14	1999-04-13	Salama; Fouad A.	Artificial sphincter urinary control system
US5954766A (en)	1997-09-16	1999-09-21	Zadno-Azizi; Gholam-Reza	Body fluid flow control device
IN186245B (fr)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
US5993473A (en)	1997-11-19	1999-11-30	Chan; Yung C.	Expandable body device for the gastric cavity and method
DE59913189D1 (de)	1998-06-25	2006-05-04	Biotronik Ag	Implantierbare, bioresorbierbare Gefässwandstütze, insbesondere Koronarstent
DE19850309A1 (de)	1998-10-30	2000-05-04	Lohmann Therapie Syst Lts	Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
US6797283B1 (en)	1998-12-23	2004-09-28	Alza Corporation	Gastric retention dosage form having multiple layers
US6267776B1 (en)	1999-05-03	2001-07-31	O'connell Paul T.	Vena cava filter and method for treating pulmonary embolism
EP2308522A3 (fr)	1999-11-17	2012-02-29	Boston Scientific Limited	Dispositifs microfabriques pour transport de molécules dans un fluide porteur
US6517659B1 (en)	1999-11-18	2003-02-11	Active Mfg. Corp.	Method for coincidentally cut and fused object
MXPA00001922A (es)	2000-02-24	2002-03-08	De Hayos Garza Andres	Cateter de balon intragastrico percutaneo para tratamiento de la obesidad.
US6503264B1 (en)	2000-03-03	2003-01-07	Bioenterics Corporation	Endoscopic device for removing an intragastric balloon
JP4619608B2 (ja)	2000-03-08	2011-01-26	ギブンイメージングリミテッド	インビボ撮像のための装置およびシステム
US8642051B2 (en)	2000-03-21	2014-02-04	Suzanne Jaffe Stillman	Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s)
JP2004501190A (ja) *	2000-06-23	2004-01-15	テバ　ファーマシューティカル　インダストリーズ　リミティド	治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
US6476006B2 (en) *	2000-06-23	2002-11-05	Teva Pharmaceutical Industries, Ltd.	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6579310B1 (en)	2000-08-17	2003-06-17	Advanced Cardiovascular Systems, Inc.	Stent having overlapping struts
US6726920B1 (en)	2000-09-22	2004-04-27	Durect Corporation	Implantable drug delivery patch
US7033373B2 (en)	2000-11-03	2006-04-25	Satiety, Inc.	Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6579301B1 (en)	2000-11-17	2003-06-17	Syntheon, Llc	Intragastric balloon device adapted to be repeatedly varied in volume without external assistance
DE60110469T2 (de)	2001-03-09	2006-02-23	Jose Rafael Garza Alvarez	Intragastrische ballonanordnung
US6833488B2 (en)	2001-03-30	2004-12-21	Exotech Bio Solution Ltd.	Biocompatible, biodegradable, water-absorbent material and methods for its preparation
US7066945B2 (en)	2001-05-17	2006-06-27	Wilson-Cook Medical Inc.	Intragastric device for treating obesity
KR20040032918A (ko)	2001-08-16	2004-04-17	더 스테이트 오브 오레곤 액팅 바이 앤드 쓰루 더 스테이트 보드 오브 하이어 에쥬케이션 온 비해프 오브 오레곤 스테이트 유니버시티	팽창 가능한 위 정지 장치
US6675809B2 (en)	2001-08-27	2004-01-13	Richard S. Stack	Satiation devices and methods
CN101810521B (zh)	2001-08-27	2015-05-13	辛尼科有限责任公司	饱满装置和方法
US6845776B2 (en)	2001-08-27	2005-01-25	Richard S. Stack	Satiation devices and methods
US6755869B2 (en)	2001-11-09	2004-06-29	Boston Scientific Corporation	Intragastric prosthesis for the treatment of morbid obesity
FR2834202B1 (fr)	2001-12-28	2004-03-19	Cie Euro Etude Rech Paroscopie	Ballon intra-gastrique a poches multiples, dispositif chirurgical d'expansion dudit ballon et procede de fabrication correspondant
US6733512B2 (en)	2002-03-07	2004-05-11	Mcghan Jim J.	Self-deflating intragastric balloon
US7335210B2 (en)	2002-04-03	2008-02-26	Julie Ann Smit	Endoscope and tools for applying sealants and adhesives and intestinal lining for reducing food absorption
US7794494B2 (en)	2002-10-11	2010-09-14	Boston Scientific Scimed, Inc.	Implantable medical devices
CH696150A5 (de)	2002-10-14	2007-01-15	Stoll Giroflex Ag	Montagebeschlag mit Bajonettkupplung.
US20040192582A1 (en)	2002-12-19	2004-09-30	Burnett Daniel R.	Ingestible formulations for transient, noninvasive reduction of gastric volume
US20040143342A1 (en)	2003-01-16	2004-07-22	Stack Richard S.	Satiation pouches and methods of use
DE10304614B4 (de)	2003-02-05	2005-02-24	Willital, Günter Heinrich, Prof. Dr.med.	Kontinenz-Vorrichtung
US6981980B2 (en)	2003-03-19	2006-01-03	Phagia Technology	Self-inflating intragastric volume-occupying device
US20060058829A1 (en)	2003-03-19	2006-03-16	Sampson Douglas C	Intragastric volume-occupying device
FR2852821B1 (fr)	2003-03-31	2007-06-01	Cie Euro Etude Rech Paroscopie	Ballon intra-gastrique enduit de parylene, procede de fabrication d'un tel ballon et utilisation de parylene pour revetir un ballon intra-gastrique
US7128759B2 (en)	2003-05-19	2006-10-31	Cook Incorporated	Implantable medical device with constrained expansion
US7632291B2 (en)	2003-06-13	2009-12-15	Trivascular2, Inc.	Inflatable implant
CA2540653C (fr)	2003-08-13	2012-09-18	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Systeme de compression pour traitement percutane de l'obesite
US7758493B2 (en)	2003-10-23	2010-07-20	Proxy Biomedical Limited	Gastric constriction device
WO2005082296A1 (fr)	2004-02-25	2005-09-09	Mayo Foundation For Medical Education And Research	Dispositifs et procedes de pontage gastrique
US7931693B2 (en)	2004-02-26	2011-04-26	Endosphere, Inc.	Method and apparatus for reducing obesity
TW200533391A (en)	2004-03-25	2005-10-16	Sun Pharmaceutical Ind Ltd	Gastric retention drug delivery system
CA2561193A1 (fr)	2004-03-26	2005-10-20	Satiety, Inc.	Systemes et methodes de traitement de l'obesite
US7112186B2 (en)	2004-05-26	2006-09-26	Shah Tilak M	Gastro-occlusive device
WO2005120363A1 (fr)	2004-06-03	2005-12-22	Mayo Foundation For Medical Education And Research	Traitement de l'obesite et dispositif associe
WO2006002399A2 (fr)	2004-06-24	2006-01-05	Surmodics, Inc.	Dispositifs medicaux biodegradables implantables, procedes et systemes associes
US20060025799A1 (en)	2004-07-27	2006-02-02	Patrick Basu	Endoscopically placed gastric balloon (EPGB) device and method for treating obesity involving the same
WO2006020929A2 (fr)	2004-08-13	2006-02-23	Phagia Technology	Dispositif place dans le volume intragastrique
US20070078476A1 (en)	2004-10-12	2007-04-05	Hull Wendell C Sr	Overweight control apparatuses for insertion into the stomach
EP2684579B1 (fr)	2004-10-15	2016-04-27	Bfkw, Llc	Dispositif contre l'obésité
US7699883B2 (en)	2004-10-25	2010-04-20	Myles Douglas	Vascular graft and deployment system
CA2586568C (fr)	2004-11-05	2014-12-02	Electronic Dietary Foods Inc.	Degradation commandee de polymeres expansibles dans un traitement de reduction du volume gastrique
US8070807B2 (en)	2004-11-19	2011-12-06	Fulfillium, Inc.	Wireless breach detection
WO2006063593A2 (fr)	2004-12-14	2006-06-22	Rune Wessel Weltlesen	Systeme et procede pour le traitement de l'obesite a l'aide d'un ballonnet intragastrique
IL166183A0 (en)	2005-01-06	2006-01-15	Yissum Res Dev Co	Novel diagnostic and imaging techniques of the gi tract
US20060155259A1 (en)	2005-01-13	2006-07-13	Maclay Alistair	Stomach balloon that can be inserted and removed via mouth
US7699863B2 (en)	2005-03-01	2010-04-20	Tulip Medical Ltd.	Bioerodible self-deployable intragastric implants
US7785291B2 (en)	2005-03-01	2010-08-31	Tulip Medical Ltd.	Bioerodible self-deployable intragastric implants
US7517914B2 (en)	2005-04-04	2009-04-14	Boston Scientificscimed, Inc.	Controlled degradation materials for therapeutic agent delivery
EP1893142B1 (fr)	2005-05-09	2013-04-24	Cook Medical Technologies LLC	Dispositif intragastrique pour traiter l'obesite
WO2007017842A2 (fr)	2005-08-09	2007-02-15	Tylerton International Inc.	Capsule permettant de ressentir un etat de satiete
US20070100368A1 (en)	2005-10-31	2007-05-03	Quijano Rodolfo C	Intragastric space filler
US20070100367A1 (en)	2005-10-31	2007-05-03	Quijano Rodolfo C	Intragastric space filler
US7674396B2 (en)	2005-11-08	2010-03-09	Plensat Llc	Method and system for treatment of eating disorders
US7879355B2 (en) *	2005-11-08	2011-02-01	Plensat Llc	Method and system for treatment of eating disorders
EP2997953B1 (fr)	2006-01-18	2018-12-26	Intec Pharma Ltd.	Dispositif d'administration par voie orale d'un agent
US20070249900A1 (en)	2006-01-19	2007-10-25	Capso Vision, Inc.	In vivo device with balloon stabilizer and valve
WO2007093999A1 (fr)	2006-02-15	2007-08-23	Intec Pharma Ltd.	Système de gastro-rétention pour dé livrer des macromolécules
US20070224234A1 (en)	2006-03-22	2007-09-27	Mark Steckel	Medical devices having biodegradable polymeric regions
WO2007109904A1 (fr)	2006-03-29	2007-10-04	Electronic Dietary Foods Inc.	accessoire ingeRABLE pour LE contrôle dU poids
RU2008142840A (ru)	2006-03-30	2010-05-10	Джелесис, Инк. (Us)	Сополимер стирола и малеинового ангидрида/кислоты (варианты), изделие на его основе, способ получения сополимера стирола и малеинового ангидрида/кислоты
US8398668B2 (en)	2006-04-19	2013-03-19	Vibrynt, Inc.	Devices and methods for treatment of obesity
US8342183B2 (en)	2006-04-19	2013-01-01	Vibrynt, Inc.	Devices and methods for treatment of obesity
US20070256709A1 (en)	2006-04-29	2007-11-08	Quanyuan Shang	Methods and apparatus for operating an inkjet printing system
JP5220001B2 (ja)	2006-05-18	2013-06-26	チューリップメディカルリミテッド	生体内分解性の自己展開式の胃内インプラントおよび胃以外のインプラント
US9642693B2 (en)	2007-04-13	2017-05-09	W. L. Gore & Associates, Inc.	Medical apparatus and method of making the same
DE102007026037A1 (de) *	2007-06-04	2008-12-11	Lts Lohmann Therapie-Systeme Ag	Gastroretentives System mit Alginat-Körper
BRPI0814439B1 (pt)	2007-07-20	2018-12-11	Imaflex, Inc.	filme de palha, filme para fumigação e/ou filme para propagação, seu processo de produção e seu uso
EP2231212A2 (fr)	2007-12-20	2010-09-29	7L, Llc	Dispositif autodilatable à avaler occupant l'espace gastrique
WO2010045477A2 (fr)	2008-10-16	2010-04-22	Obalon Therapeutics, Inc.	Dispositif occupant un volume intra-gastrique et son procédé de fabrication
US20110066175A1 (en) *	2009-05-07	2011-03-17	Rainbow Medical Ltd.	Gastric anchor
US8292911B2 (en)	2011-01-21	2012-10-23	Obalon Therapeutics, Inc.	Intragastric device
US8647358B2 (en)	2011-01-21	2014-02-11	Obalon Therapeutics Inc.	Intragastric device
US8202291B1 (en)	2011-01-21	2012-06-19	Obalon Therapeutics, Inc.	Intragastric device
NO3117865T3 (fr)	2011-01-21	2018-04-07
US9119793B1 (en)	2011-06-28	2015-09-01	Medicis Pharmaceutical Corporation	Gastroretentive dosage forms for doxycycline
RU2601995C2 (ru)	2012-02-21	2016-11-10	Аллюрион Текнолоджиз, Инк.	Способы и устройство для внедрения временного имплантата в тело и извлечения временного имплантата из тела
WO2013183058A2 (fr) *	2012-06-07	2013-12-12	Tulip Medical Ltd.	Dispositif étendu
EP3091962B1 (fr) *	2013-12-05	2022-06-08	Epitomee Medical Ltd.	Dispositifs et systèmes de rétention pour la libération in-situ d'agents pharmaceutiques actifs

2014
- 2014-12-04 EP EP14824124.3A patent/EP3091962B1/fr active Active
- 2014-12-04 CN CN201480072619.1A patent/CN105899198A/zh active Pending
- 2014-12-04 CA CA2932574A patent/CA2932574C/fr active Active
- 2014-12-04 BR BR112016012615-7A patent/BR112016012615B1/pt active IP Right Grant
- 2014-12-04 AU AU2014358675A patent/AU2014358675B2/en active Active
- 2014-12-04 CN CN202210337069.8A patent/CN114668960A/zh active Pending
- 2014-12-04 ES ES14824124T patent/ES2926480T3/es active Active
- 2014-12-04 US US15/101,045 patent/US11129793B2/en active Active
- 2014-12-04 WO PCT/IL2014/051063 patent/WO2015083171A1/fr not_active Ceased
- 2014-12-04 JP JP2016536242A patent/JP2017502935A/ja active Pending
2016
- 2016-06-02 IL IL245987A patent/IL245987B/en active IP Right Grant
2019
- 2019-07-26 JP JP2019137497A patent/JP7291025B2/ja active Active
2021
- 2021-09-13 JP JP2021148642A patent/JP2021193122A/ja active Pending

Also Published As

Publication number	Publication date
AU2014358675B2 (en)	2019-10-03
BR112016012615A2 (pt)	2017-08-08
US20180250226A1 (en)	2018-09-06
JP2021193122A (ja)	2021-12-23
BR112016012615A8 (pt)	2023-01-03
IL245987B (en)	2020-04-30
IL245987A0 (en)	2016-07-31
JP7291025B2 (ja)	2023-06-14
CA2932574A1 (fr)	2015-06-11
AU2014358675A1 (en)	2016-06-16
CN105899198A (zh)	2016-08-24
EP3091962A1 (fr)	2016-11-16
CN114668960A (zh)	2022-06-28
CA2932574C (fr)	2023-03-07
BR112016012615B1 (pt)	2023-02-07
JP2017502935A (ja)	2017-01-26
US11129793B2 (en)	2021-09-28
EP3091962B1 (fr)	2022-06-08
WO2015083171A1 (fr)	2015-06-11
JP2019196396A (ja)	2019-11-14

Publication	Publication Date	Title
ES2926480T3 (es)	2022-10-26	Dispositivos y sistemas retentivos para la liberación in situ de principios activos farmacéuticos
ES2981892T3 (es)	2024-10-11	Dispositivo expandido
ES2270982T3 (es)	2007-04-16	Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
ES2392396T3 (es)	2012-12-10	Sistema de suministro de fármacos por difusión/bombeo osmótico combinados
ES2389729T3 (es)	2012-10-30	Sistema de retención gástrica
ES2260253T3 (es)	2006-11-01	Composicion farmaceutica oral de liberacion controlada y absorcion prolongada.
Porwal et al.	2017	Decades of research in drug targeting using gastroretentive drug delivery systems for antihypertensive therapy
Pandey et al.	2012	A review on current approaches in gastro retentive drug delivery system
ES2370239T3 (es)	2011-12-13	Sistemas modulares para la liberación controlada de una sustancia con control de espacio y tiempo.
Sanjay et al.	2009	Gastroretentive drug delivery system: Current approaches
Kumari	2018	Recent Development inFloating Drug Delivery System: A Review
Kandwal et al.	2014	Floating drug delivery system: A novel approach
Rajak et al.	2011	Gastroretentive floating drug delivery system: an approach in gastroretentive drug delivery
Bhoyar et al.	2012	An overview of a gastro retentive floating drug delivery system
Omidian et al.	2010	Oral targeted drug delivery systems: gastric retention devices
Shah et al.	2010	A novel approach in gastro retentive drug delivery system: floating drug delivery system
Kulkarni et al.	2024	Gastroretentive Drug Delivery Systems
Kharat et al.	2023	RECENT INNOVATIONS IN GASTRO-RETENTIVE DRUG DELIVERY SYSTEM AND ITS PROSPECT IN THE FUTURE
Pancholi	2011	Formulation approaches to enhance the bioavailability of narrow absorption window drugs
Sandhya et al.	2016	GASTRORETENTIVE DOSAGE FORMS AS ORAL CONTROLLED DRUG DELIVERY: A REVIEW
Gouda et al.	2011	An Overview on Various Approaches for Gastroretentive Drug Delivery systems
Wagh et al.	2014	FLOATING DRUG DELIVERY SYSTEM: AN APPROACH TO GASTRO RETENTION
Sahu et al.	2011	Gastroretentive Drug Delivery Systems
KANDWAL et al.	2015	Indian Journal of Novel Drug Delivery
Madhavi	0	Comprehensive Review on Gastro Retentive Drug Delivery System